Trowbridge Stephen A

SEC source: 0001140361-26-029634 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 57,381 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029634 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,796

F2 · shares: The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029634 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,562

F3 · shares: The exempt disposition of 717 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,279

F2 · shares: The exempt disposition of 3,510 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,789

F1 · shares: The exempt disposition of 7,840 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029334 · form4.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,257

Underlying: Common Stock · 53,257 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029334 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,819

F1 · shares: The acquisition of 53,257 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 53,257 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-25-038018 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,629

SEC source: 0001140361-25-026800 · form4.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,739

F3 · shares: The exempt disposition of 667 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-25-026800 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,406

F2 · shares: The exempt disposition of 717 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-25-026800 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,123

F1 · shares: The exempt disposition of 2,585 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-25-026462 · form4.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,997

Underlying: Common Stock · 86,997 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-25-026462 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,708

F1 · shares: The acquisition of 86,997 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 86,997 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.

SEC source: 0001140361-24-043173 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,711

SEC source: 0001140361-24-034268 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,470

F2 · shares: The exempt disposition of 667 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-034268 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,137

F1 · shares: The exempt disposition of 717 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-24-035597 · form4.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,011

F3 · shares: The exempt disposition of 2,585 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-24-033629 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,458

Underlying: Common Stock · 76,458 shares

Expires 2034-07-17

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-033629 · form4.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,905

Underlying: Common Stock · 77,905 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-24-033629 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,854

F1 · shares: The acquisition of 38,953 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 38,953 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-035597 · form4.xml · derivative · entry 4

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,817 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F4 · derivative.exercise_date: On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F4 · derivative.expiration_date: On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-24-035597 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,596

F2 · shares: The exempt disposition of 4,016 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-035597 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 11,142 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-011190 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,901

F1 · kind: These shares were acquired under the AngioDynamics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001140361-23-036121 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,595

F2 · shares: The exempt disposition of 667 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036121 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,262

F1 · shares: The exempt disposition of 717 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-23-035726 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,378

Underlying: Common Stock · 59,378 shares

Expires 2033-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-035726 · form4.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,381

Underlying: Common Stock · 57,381 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-23-035726 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,979

F1 · shares: The acquisition of 28,691 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 28,691 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-036318 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-036318 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,205

F2 · shares: The exempt disposition of 3,159 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036318 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 8,769 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044840 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 19,354 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044840 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,974

F2 · shares: The exempt disposition of 6,975 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044840 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,949

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 19,354 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035087 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,288

F2 · shares: The exempt disposition of 376 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035087 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,664

F1 · shares: The exempt disposition of 1,362 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-23-002005 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,026

F1 · shares: The exempt disposition of 555 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 3, 2020.

SEC source: 0001567619-22-018449 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,581

SEC source: 0001567619-22-014367 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,650

Underlying: Common Stock · 18,650 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014367 · doc1.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,922

Underlying: Common Stock · 15,922 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014367 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,498

F1 · shares: The acquisition of 7,961 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,961 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014114 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,758 shares

Expires 2022-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares were each exercisable beginning 7/22/2016, 7/22/2017, 7/22/2018 and 7/22/2019, respectively.

SEC source: 0001567619-22-014114 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,537

F1 · shares: The exempt disposition of 12,398 shares of common stock of AngioDynamics, Inc. (the "Company") to the Company was made to satisfy the exercise price arising from a net (cashless) exercise of stock options that were set to expire on 7/22/2022.

SEC source: 0001567619-22-014114 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-013844 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 4,188 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 4,188 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 8,357 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 4,188 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001567619-22-013844 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,177

F2 · shares: The exempt disposition of 1,509 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-013844 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 4,188 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-002518 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,498

F1 · shares: The exempt disposition of 583 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 3, 2020.